Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
Type:
Grant
Filed:
November 10, 2008
Date of Patent:
April 24, 2012
Assignee:
N.V. Innogenetics S.A.
Inventors:
Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Vandevoorde
Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
Type:
Application
Filed:
November 10, 2008
Publication date:
June 16, 2011
Applicant:
N.V. Innogenetics S. A.
Inventors:
Marc Mercken, Ev-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Vandevoorde
Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
Type:
Application
Filed:
November 10, 2008
Publication date:
May 28, 2009
Applicant:
N.V. Innogenetics S. A.
Inventors:
Marc Mercken, Ev-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Vandevoorde
Abstract: The invention relates to recombinant polypeptides and peptides and particularly to the polypeptide containing in its polypeptidic chain the following amino acid sequence: the one extending from the extremity constituted by nucleotide at position (1) to the extremity constituted by nucleotide at position (194) represented in FIG. 4a and FIG. 4b. The polypeptides and peptides of the invention can be used for the diagnostic of tuberculosis, and can also be part of the active principle in the preparation of vaccine against tuberculosis.
Type:
Grant
Filed:
June 22, 2006
Date of Patent:
October 9, 2007
Assignee:
N.V. Innogenetics S.A.
Inventors:
Jean Content, Lucas De Wit, Jacqueline De Bruyn, Jean-Paul Van Vooren
Abstract: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8 023 to 8 235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as show in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.
Abstract: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8 023 to 8 235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.
Abstract: The present application provides polynucleic acid sequences of 8 or more contiguous nucleotides selected from an HCV subtype 3c genomic sequence selected from the region spanning positions 1 to 957 of the Core of Core/E1 region of HCV subtype 3c, wherein said polynucleic acid sequence is capable of hybridizing to HCV type 3c, but not another type or subtype of HCV; or the complement of the polynucleic acid, wherein the polynucleic acid contains at least one genotype-specific nucleotide. Methods and means of using and making the described sequences are also provided.
Abstract: The invention relates to recombinant polypeptides and peptides and particularly to the polypeptide containing in its polypeptidic chain the following amino acid sequence: the one extending from the extremity constituted by nucleotide at position (1) to the extremity constituted by nucleotide at position (194) represented in FIG. 4a and FIG. 4b. The polypeptides and peptides of the invention can be used for the diagnostic of tuberculosis, and can also be part of the active principle in the preparation of vaccine against tuberculosis.
Type:
Grant
Filed:
December 23, 2002
Date of Patent:
August 1, 2006
Assignee:
N.V. Innogenetics S.A.
Inventors:
Jean Content, Lucas De Wit, Jacqueline De Bruyn, Jean-Paul Van Vooren
Abstract: Multimer peptides (e.g. 30- to 45-mer peptides) derived from hepatitis C virus envelope proteins reacting with the majority of anti-HCV antibodies present in patient sera are described. The usage of the latter peptides to diagnose, and to vaccinate against, an infection with hepatitis C virus is also disclosed.
Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein can be obtained from a brain homogenate, itslf isolated from the cerebral cortex of a patient having Alzheimer's disease. Further, a method of detecting the tau protein is claimed.
Type:
Application
Filed:
August 20, 2004
Publication date:
January 12, 2006
Applicant:
N.V. Innogenetics S.A.
Inventors:
Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Van De Voorde
Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein ca be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
Abstract: Multimer peptides (e.g. 30- to 45-mer peptides) derived from hepatitis C virus envelope proteins reacting with the majority of anti-HCV antibodies present in patient sera are described. The usage of the latter peptides to diagnose, and to vaccinate against, an infection with hepatitis C virus is also disclosed.
Abstract: Multimer peptides (e.g. 30- to 45-mer peptides) derived from hepatitis C virus envelope proteins reacting with the majority of anti-HCV antibodies present in patient sera are described. The usage of the latter peptides to diagnose, and to vaccinate against, an infection with hepatitis C virus is also disclosed.
Abstract: This invention is directed toward a peptide corresponding to an immunologically important viral epitope. Specifically, the peptide corresponds to an immunodominant epitope identified in the envelope region of the human immunodeficiency virus type 1 (HIV-1). This peptide has the following amino acid sequence: NH2-Asn-Asn-Thr-Arg-Arg-Gly-Ile-His-Met-Gly-Trp-Gly-Arg-Thr-Phe-Tyr-Ala-Thr-Gly-Glu-Ile-Ile-Gly-CO2H (SEQ ID NO:17). The invention also relates to the use of this peptide, particularly when biotinylated in the form of complexes of streptavidin-biotinylated peptides or of avidin-biotinylated peptides, for the in vitro determination of HIV-1-specific antibodies.
Abstract: The invention relates to a probe consisting of at least about 15 nucleotides from the spacer region between rRNA genes of a non-viral organism, particularly prokaryotic organism and more particularly bacteria, and preferably from about 15 nucleotides to about the maximum number of nucleotides of the spacer region and more preferably from about 15 to about 100 nucleotides to be used for the detection of non-viral microorganisms.
Abstract: This invention is directed toward a peptide corresponding to an immunologically important viral epitope. Specifically, the peptide corresponds to an immunodominant epitope identified in the gp41 region of the human immunodeficiency virus type 1 (HIV-1), strain Ant70. This peptide has the following amino acid sequence: NH2-Leu-Trp-Gly-Cys-Lys-Gly-Lys-Leu-Val-Cys-CO2H. The invention also relates to the use of this peptide, particularly when biotinylated in the form of complexes of streptavidin-biotinylated peptides or of avidin-biotinylated peptides, for the in vitro determination of HIV-1-specific antibodies.
Abstract: The invention relates to recombinant polypeptides and peptides and particularly to the polypeptide containing in its polypeptidic chain the following amino acid sequence: the one extending from the extremity constituted by nucleotide at position (1) to the extremity constituted by nucleotide at position (194) represented in FIG. 4a and FIG. 4b. The polypeptides and peptides of the invention can be used for the diagnostic of tuberculosis, and can also be part of the active principle in the preparation of vaccine against tuberculosis.
Type:
Application
Filed:
December 23, 2002
Publication date:
December 4, 2003
Applicant:
N.V. Innogenetics S.A., a Belgium corporation
Inventors:
Jean Content, Lucas De Wit, Jacqueline De Bruyn, Jean-Paul Van Vooren
Abstract: The invention relates to a probe consisting of at least about 15 nucleotides from the spacer region between rRNA genes of a non-viral organism, particularly prokaryotic organism and more particularly bacteria, and preferably from about 15 nucleotides to about the maximum number of nucleotides of the spacer region and more preferably from about 15 to about 100 nucleotides to be used for the detection of non-viral microorganisms.